T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The designed study follows up the retrospective previous one by the International T-cell Non-Hodgkin's Lymphoma Study Group (International Peripheral T-Cell Lymphoma Project). It is designed as a prospective collection of information potentially useful to predict the prognosis of newly diagnosed patients with the more frequent subtypes of Peripheral T-cell lymphoma (Peripheral T-cell lymphoma unspecified and Angioimmunoblastic T-cell lymphoma) and to better define clinical characteristics and outcome of the more uncommon subtypes

Official Title

Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. 1. Previously-untreated patients with de novo diagnosis of peripheral T-cell or NK/T-cell lymphoma: - Peripheral T-cell lymphoma unspecified; - Peripheral T-cell lymphoma, lymphoepithelioid variant; - Peripheral T-cell lymphoma, T-zone variant ; - Peripheral T-cell lymphoma, parafollicular variant ; - Angioimmunoblastic T-cell lymphoma; - Nasal NK/T-cell lymphoma; - NK/T-cell lymphoma, nasal time; - Anaplastic large-cell lymphoma, T/null cell, ALK+, primary systemic type - Anaplastic large-cell lymphoma, T/null cell, ALK-, primary systemic type - Anaplastic large cell lymphoma, small cell variant, ALK+ - Anaplastic large cell lymphoma, lymphohistiocytic variant, ALK+ - Enteropathy- type T-cell lymphoma; - Hepatosplenic T-cell lymphoma; - Peripheral gamma-delta T-cell lymphoma; - Subcutaneous panniculitis-like T-cell lymphoma; - Unclassifiable peripheral T-cell Lymphoma - Unclassifiable NK-cell lymphoma 2. Age over 18 3. Tissue biopsies adequate for diagnosis and classification and available for centralized review 4. Clinical data including baseline information on disease localization and laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating for at least 5 years are requested 5. Written informed consent
Exclusion Criteria:
  1. 1. Age < 18 2. Diagnosis of T-cell or NK-cell leukemia or proliferation and other than mature types including: - Adult T-cell leukemia/lymphoma; - Blastic NK-cell leukemia/lymphoma; - Aggressive NK-cell leukemia - T-cell large granular lymphocytic leukemia - T-cell large granular lymphocytic proliferation - NK-cell large granular lymphocytic proliferation - T-cell prolymphocytic leukemia - Precursor T-cell lymphoblastic leukemia/lymphoma - Mycosis fungoides; - Sézary syndrome; - Primary cutaneous ALCL


Ranjana Advani
Ranjana Advani
Lymphoma specialist, Hematologist-Oncologist
Saul A. Rosenberg, MD, Professor of Lymphoma

Contact us to find out if this trial is right for you.